Belkahla, S Hakem1, N Boumansour2, N
Midoun2. Risk factors of hepatic fibrosis at the
chronic carriers of virus B followed at Oran
university hospital center. Algerian Journal of
Health Sciences. Vol. 01 Num. 01. 2019. 21-26
[4]. Llorenç Caballería et al. High Prevalence of
Liver Fibrosis Among European Adults With
Unknown Liver Disease: A Population-Based
Study. Clinical Gastroenterology and
Hepatology 2018; 16:1138–1145
[5]. Chalasani N, Younossi Z, Lavine JE, et al. The
diagnosis and management of non-alcoholic
fatty liver disease: practice. Guidance from the
American Association for the Study of Liver
Diseass. Hepatology 2018; 67:328–357.
[6]. European Association for the Study of the
Liver (EASL); European Association for the
Study of Diabetes (EASD); European.
Association for the Study of Obesity (EASO).
EASL-EASD-EASO Clinical Practice
Guidelines for the management of nonalcoholic
fatty liver disease. J Hepatol 2016; 64:1388–
1402.
[7]. Younossi ZM, Koenig AB, Abdelatif D, et al.
Global epidemiology of nonalcoholic fatty liver
disease-meta-analytic assessment of
prevalence, incidence, and outcomes.
Hepatology 2016; 64:73–84.
[8]. Satapathy SK, Sanyal AJ. epidemiology and
natural history of nonalcoholic fatty liver
disease.Semin Liver Dis 2015; 35:221–235.
[9]. Ginès P, Graupera I, Lammert F, et al.
Screening for liver fibrosis in the general
population: a call for action. Lancet
Gastroenterol Hepatol 2016; 1:256–260.
[10]. Adams LA, Lymp JF, St Sauver J,
Sanderson SO, Lindor KD, Feldstein A,
Angulo P. The natural history of nonalcoholic
fatty liver disease: a population-based cohort
study. Gastroenterology 2005; 129: 113-121.
DOI: 10.1053/ j.gastro.2005.04.014]
[11]. Sombat Treeprasertsuk, Einar Björnsson,
Felicity Enders, Sompongse Suwanwalaikorn,
Keith D Lindor. NAFLD fibrosis score: A
prognostic predictor for mortality and liver
complications among NAFLD patients. World
J Gastroenterol 2013 February 28; 19(8): 1219-
1229
[12]. World health organization. Global hepatitis
report, 2017. Geneva : WHO, 2017.
[13]. European Association for the Study of the
Liver. EASL clinical practice guidelines:
management of chronic hepatitis B virus
infection. J Hepatol 2012; 57 : 167-85.
[14]. Ferlay J, Soerjomataram I, Dikshit R, et al.
Cancer incidence and mortality worldwide:
Sources, methods and major patterns in
GLOBOCAN 2012: Globocan 2012. Int J
Cancer 2015 ; 136 : E359-86.
[15]. Thomas DL, Seeff LB. Natural history of
hepatitis C. Clin Liver Dis 2005. 9: 383,98,
DOI:https://doi.org/10.1016/j.cld.2005.05.003.
[16]. Massard J, Ratziu V, Thabut D, Moussalli
J, Lebray P, et al. Natural history and
predictors of disease severity in chronic
hepatitis C. J Hepatol. 2006; 44: S19–S24
DOI:https://doi.org/10.1016/j.jhep.2005.11.009
.
[17]. Davis GL, Lau JY. Factors predictive of a
beneficial response to therapy of hepatitis C.
Hepatology. 1997. 26: 122S–127S DOI:
https://doi.org/10.1002/hep.51026071
[18]. Poynard T, Ratziu V, Charlotte F,
Goodman Z, McHutchison J, et al. Rates and
risk factors of liver fibrosis progression in
patients with chronic hepatitis c. J Hepatol
2001. 34: 730–739.
[19]. Sulkowski MS, Thomas DL Hepatitis C in
the HIV-Infected Person. Ann Intern Med
2003; 138: 197–207.
[20]. Bouharati K., Bouharati I., Guenifi W.,
Gasmi A., Laouamri S. Intelligent analysis of
some factors accompanying hepatitis B.
Molecular Sciences and Applications DOI:
10.37394/232023. 2022.2.7
[21]. Mnih, V. et al. Human-level control
through deep reinforcement learning. Nature
2015; 518, 529–533
[22]. Bouharati I., El-Hachmi S., Babouche F.,
Khenchouche A., Bouharati K., Bouharati S.
Radiology and management of recurrent
varicose veins: Risk factors analysis using
artificial neural networks. 2018. Volume: 5
Number:1 Pages No:1–5.
10.15713/ins.jmrps.116
[23]. Khenchouche A., Bouharati K., Bouharati S.,
Mahnane A., Hamdi-Cherif M. Post Mortem
Interval: Necrobiome Analysis Using Artificial
Neural Networks. Computational Biology and
Bioinformatics. 2017. 5(6): 90-96.
Creative Commons Attribution License 4.0
(Attribution 4.0 International, CC BY 4.0)
This article is published under the terms of the Creative
Commons Attribution License 4.0
https://creativecommons.org/licenses/by/4.0/deed.en_US
WSEAS TRANSACTIONS on BIOLOGY and BIOMEDICINE
DOI: 10.37394/23208.2022.19.17
Bouharati Imene, Boubendir Nasser-Dine,
Bouharati Khaoula, Laouamri Slimane